# Totient

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/totient

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.totient.bio
- Total disclosed funding: $10M
- Latest round: Seed (Sep 10, 2020)
- Investors on record: 5

## About

Totient is a biotech company specializing in the development of innovative antibody therapeutics, leveraging cutting-edge technology to address significant health challenges globally.Founded in 2017 and headquartered in Cambridge, US, Totient focuses on the creation of biologic therapeutics. The company was acquired by AbSci, LLC in June 2021, although financial terms of the acquisition have not been disclosed. The CEO and founder, Deniz Kural, has a background in biotechnology and has previously been involved in related ventures.Totient specializes in developing biologic therapeutics, particularly through its proprietary TL1A antibody aimed at treating Inflammatory Bowel Disease (IBD). Utilizing an Integrated Drug Creation Platform, Totient employs advanced artificial intelligence and iterative lab processes to streamline drug development, reducing the time frame from conception to clinical trials to approximately 24 months. This platform identifies new biological targets and produces specific antibodies, catering to pharmaceutical companies and research institutions primarily in North America and Europe.Totient generates revenue through partnerships and collaborations with pharmaceutical companies, engaging in B2B transactions. Their business model includes subscription-based agreements for access to their Integrated Drug Creation Platform, alongside milestone-driven payments associated with the successful development of drug candidates. Each collaboration is structured to meet specific client needs, including the design and optimization of biologics, aligning revenue strategies with market demands in the biopharmaceutical sector.With recent funding from the Seed round in June 2021, where Totient raised USD 10.00 mn from investors including Kaitai Capital and Mission BioCapital, the company plans to expand its product offerings and enhance its drug development capabilities. Future products are anticipated to launch within the next few years as they continue to innovate in antibody therapeutics. The company is also looking to broaden its market reach into new geographic regions, particularly targeting Asia and Europe, to meet the growing demand for biologic treatments.

## Funding rounds

- Seed, Sep 10, 2020, $10M — Kaitai Capital, Sands Capital Alternatives, Mission Biocapital, Viva Biotech Holdings, Tau Ventures

## Investors

- Kaitai Capital (https://capitalatlas.ai/funds/kaitai-capital) — Seed
- Sands Capital Alternatives (https://capitalatlas.ai/funds/sands-capital-alternatives) — Seed
- Mission Biocapital (https://capitalatlas.ai/funds/mission-biocapital) — Seed
- Viva Biotech Holdings — Seed
- Tau Ventures — Seed